| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 16 | 2024 | 612 | 3.910 |
Why?
|
| Heparin | 16 | 2023 | 226 | 2.790 |
Why?
|
| Anticoagulants | 19 | 2024 | 592 | 2.530 |
Why?
|
| Thrombosis | 12 | 2023 | 522 | 2.480 |
Why?
|
| Hemorrhage | 11 | 2022 | 468 | 2.300 |
Why?
|
| Blood Coagulation | 12 | 2023 | 123 | 2.070 |
Why?
|
| Antithrombins | 7 | 2024 | 56 | 1.930 |
Why?
|
| Thrombelastography | 7 | 2021 | 57 | 1.840 |
Why?
|
| Partial Thromboplastin Time | 7 | 2021 | 47 | 1.760 |
Why?
|
| Hemostasis | 8 | 2024 | 69 | 1.730 |
Why?
|
| Heart-Assist Devices | 11 | 2024 | 1022 | 1.610 |
Why?
|
| Blood Coagulation Disorders | 7 | 2021 | 103 | 1.550 |
Why?
|
| Hirudins | 5 | 2024 | 37 | 1.380 |
Why?
|
| Erythrocyte Transfusion | 7 | 2025 | 129 | 1.250 |
Why?
|
| Hemostatics | 4 | 2021 | 57 | 1.240 |
Why?
|
| Blood Coagulation Tests | 9 | 2021 | 62 | 1.220 |
Why?
|
| Drug Monitoring | 5 | 2020 | 172 | 1.180 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2020 | 354 | 1.160 |
Why?
|
| von Willebrand Diseases | 4 | 2019 | 51 | 1.150 |
Why?
|
| Factor VIII | 4 | 2020 | 45 | 1.030 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2015 | 53 | 1.010 |
Why?
|
| Peptide Fragments | 6 | 2024 | 779 | 1.010 |
Why?
|
| ADAM Proteins | 3 | 2015 | 78 | 0.990 |
Why?
|
| Thrombophilia | 3 | 2022 | 44 | 0.910 |
Why?
|
| Citrates | 1 | 2024 | 22 | 0.880 |
Why?
|
| Citric Acid | 1 | 2024 | 36 | 0.870 |
Why?
|
| Plasma | 3 | 2020 | 98 | 0.860 |
Why?
|
| Factor Xa | 3 | 2017 | 17 | 0.840 |
Why?
|
| Blood Transfusion | 4 | 2022 | 310 | 0.790 |
Why?
|
| Fetal Blood | 3 | 2016 | 176 | 0.790 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 1115 | 0.780 |
Why?
|
| Factor V | 3 | 2022 | 18 | 0.760 |
Why?
|
| Humans | 92 | 2025 | 124867 | 0.750 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 28 | 0.720 |
Why?
|
| Child | 41 | 2024 | 24399 | 0.680 |
Why?
|
| Fibrinogen | 6 | 2024 | 154 | 0.680 |
Why?
|
| Infant, Newborn | 18 | 2024 | 8199 | 0.640 |
Why?
|
| Blood Platelets | 7 | 2020 | 327 | 0.620 |
Why?
|
| Hemoglobins | 3 | 2015 | 309 | 0.610 |
Why?
|
| Placenta Accreta | 5 | 2019 | 157 | 0.610 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2014 | 35 | 0.570 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 428 | 0.570 |
Why?
|
| Menorrhagia | 3 | 2013 | 75 | 0.570 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2014 | 14 | 0.560 |
Why?
|
| Recombinant Proteins | 5 | 2023 | 1392 | 0.560 |
Why?
|
| Vitamin K Deficiency | 1 | 2016 | 3 | 0.530 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 41 | 0.520 |
Why?
|
| Vitamin K | 1 | 2016 | 37 | 0.510 |
Why?
|
| Warfarin | 3 | 2012 | 119 | 0.510 |
Why?
|
| Retrospective Studies | 30 | 2025 | 16336 | 0.500 |
Why?
|
| Child, Preschool | 27 | 2024 | 14018 | 0.500 |
Why?
|
| Infant | 22 | 2024 | 12473 | 0.490 |
Why?
|
| Protein Precursors | 1 | 2016 | 152 | 0.490 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 225 | 0.490 |
Why?
|
| Heart Defects, Congenital | 3 | 2023 | 1815 | 0.470 |
Why?
|
| Female | 49 | 2024 | 66655 | 0.470 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 170 | 0.460 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 100 | 0.460 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2014 | 4 | 0.460 |
Why?
|
| Fibrinolysin | 1 | 2014 | 12 | 0.460 |
Why?
|
| Hysterectomy | 5 | 2019 | 189 | 0.450 |
Why?
|
| Health Information Systems | 1 | 2014 | 32 | 0.440 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 64 | 0.440 |
Why?
|
| Bilirubin | 1 | 2014 | 122 | 0.440 |
Why?
|
| Plasma Exchange | 3 | 2018 | 84 | 0.430 |
Why?
|
| Anemia, Sickle Cell | 3 | 2025 | 338 | 0.430 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2013 | 11 | 0.430 |
Why?
|
| Blood Banks | 2 | 2015 | 12 | 0.420 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 141 | 0.420 |
Why?
|
| von Willebrand Factor | 5 | 2024 | 196 | 0.410 |
Why?
|
| Platelet Function Tests | 5 | 2015 | 40 | 0.400 |
Why?
|
| beta-Alanine | 1 | 2012 | 8 | 0.400 |
Why?
|
| Blood Platelet Disorders | 1 | 2012 | 13 | 0.400 |
Why?
|
| Riots | 1 | 2012 | 2 | 0.390 |
Why?
|
| Blood Safety | 1 | 2012 | 4 | 0.390 |
Why?
|
| Blood Loss, Surgical | 5 | 2019 | 154 | 0.390 |
Why?
|
| Adolescent | 24 | 2023 | 19336 | 0.380 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 257 | 0.380 |
Why?
|
| Benzimidazoles | 1 | 2012 | 132 | 0.370 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 2 | 0.350 |
Why?
|
| Preoperative Care | 1 | 2012 | 356 | 0.340 |
Why?
|
| Thrombin | 1 | 2010 | 59 | 0.330 |
Why?
|
| Disseminated Intravascular Coagulation | 3 | 2022 | 67 | 0.330 |
Why?
|
| Male | 34 | 2024 | 61375 | 0.330 |
Why?
|
| Biomarkers | 2 | 2016 | 3069 | 0.330 |
Why?
|
| Databases, Factual | 1 | 2014 | 1179 | 0.320 |
Why?
|
| Prothrombin Time | 4 | 2016 | 36 | 0.300 |
Why?
|
| Platelet Transfusion | 3 | 2019 | 53 | 0.300 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 370 | 0.300 |
Why?
|
| Blood Component Removal | 2 | 2012 | 32 | 0.290 |
Why?
|
| Prospective Studies | 8 | 2024 | 6148 | 0.290 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.280 |
Why?
|
| Adult | 18 | 2024 | 29562 | 0.280 |
Why?
|
| Enoxaparin | 2 | 2017 | 42 | 0.280 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 203 | 0.270 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2007 | 142 | 0.270 |
Why?
|
| Serologic Tests | 1 | 2007 | 118 | 0.270 |
Why?
|
| Hemolysis | 2 | 2025 | 112 | 0.270 |
Why?
|
| Stroke | 3 | 2023 | 987 | 0.270 |
Why?
|
| Heart Transplantation | 2 | 2023 | 855 | 0.260 |
Why?
|
| Aspirin | 2 | 2008 | 222 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 268 | 0.250 |
Why?
|
| Antithrombin III | 2 | 2017 | 25 | 0.250 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2154 | 0.250 |
Why?
|
| Immunologic Factors | 1 | 2007 | 175 | 0.250 |
Why?
|
| Heart Failure | 3 | 2023 | 2285 | 0.250 |
Why?
|
| Prothrombin | 2 | 2016 | 25 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1268 | 0.240 |
Why?
|
| Age Factors | 6 | 2018 | 2822 | 0.240 |
Why?
|
| Hypersensitivity | 2 | 2021 | 183 | 0.240 |
Why?
|
| Pregnancy | 9 | 2022 | 7174 | 0.230 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.230 |
Why?
|
| Treatment Outcome | 10 | 2025 | 12398 | 0.230 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2003 | 6 | 0.220 |
Why?
|
| Protein S | 2 | 2016 | 10 | 0.220 |
Why?
|
| Protein C | 2 | 2016 | 21 | 0.220 |
Why?
|
| Young Adult | 8 | 2023 | 9047 | 0.220 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 66 | 0.210 |
Why?
|
| Activated Protein C Resistance | 1 | 2022 | 2 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 122 | 0.210 |
Why?
|
| Time Factors | 6 | 2022 | 6319 | 0.210 |
Why?
|
| Egypt | 2 | 2013 | 23 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2024 | 213 | 0.200 |
Why?
|
| Fibrinolysis | 2 | 2014 | 41 | 0.200 |
Why?
|
| Protein C Deficiency | 1 | 2022 | 12 | 0.200 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2013 | 19 | 0.200 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 80 | 0.200 |
Why?
|
| Isoantibodies | 2 | 2013 | 72 | 0.190 |
Why?
|
| Referral and Consultation | 1 | 2005 | 540 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.180 |
Why?
|
| Syndrome | 2 | 2025 | 1120 | 0.180 |
Why?
|
| Afibrinogenemia | 1 | 2021 | 10 | 0.180 |
Why?
|
| Critical Illness | 2 | 2024 | 602 | 0.180 |
Why?
|
| Cesarean Section | 4 | 2019 | 387 | 0.180 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 34 | 0.180 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 96 | 0.180 |
Why?
|
| Heparitin Sulfate | 1 | 2020 | 21 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 12 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 136 | 0.170 |
Why?
|
| Coagulants | 1 | 2019 | 7 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2021 | 82 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 207 | 0.170 |
Why?
|
| Liver Failure | 1 | 2020 | 89 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2019 | 36 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 777 | 0.150 |
Why?
|
| Factor IX | 3 | 2023 | 15 | 0.150 |
Why?
|
| Blood Coagulation Factors | 2 | 2023 | 35 | 0.150 |
Why?
|
| Materials Testing | 1 | 2018 | 73 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 1198 | 0.150 |
Why?
|
| Exercise | 1 | 2024 | 817 | 0.150 |
Why?
|
| Models, Biological | 3 | 2017 | 1458 | 0.150 |
Why?
|
| Surface Properties | 1 | 2018 | 81 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 126 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 52 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2019 | 479 | 0.140 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 399 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 3435 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 141 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2018 | 241 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2017 | 89 | 0.130 |
Why?
|
| ADAMTS13 Protein | 2 | 2014 | 62 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 18 | 0.130 |
Why?
|
| Staphylococcus aureus | 2 | 2012 | 460 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 131 | 0.130 |
Why?
|
| Pediatrics | 1 | 2005 | 1165 | 0.130 |
Why?
|
| Blood Donors | 2 | 2015 | 62 | 0.130 |
Why?
|
| Inventories, Hospital | 1 | 2015 | 1 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1151 | 0.120 |
Why?
|
| Platelet Adhesiveness | 1 | 2015 | 40 | 0.120 |
Why?
|
| Drug Resistance | 2 | 2008 | 257 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 500 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 506 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2015 | 29 | 0.120 |
Why?
|
| Term Birth | 1 | 2015 | 32 | 0.120 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 28 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1692 | 0.120 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 7 | 0.120 |
Why?
|
| Placenta, Retained | 1 | 2014 | 12 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 558 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1038 | 0.120 |
Why?
|
| Thromboxane B2 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 134 | 0.110 |
Why?
|
| Cattle | 2 | 2018 | 565 | 0.110 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 6 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2016 | 314 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 491 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 64 | 0.110 |
Why?
|
| Granulocytes | 1 | 2014 | 65 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2023 | 3069 | 0.110 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2013 | 8 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2015 | 359 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 10 | 0.100 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 15 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 267 | 0.100 |
Why?
|
| Dabigatran | 1 | 2012 | 27 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 37 | 0.100 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 23 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 129 | 0.100 |
Why?
|
| Neutropenia | 1 | 2014 | 200 | 0.100 |
Why?
|
| Arginine | 1 | 2014 | 332 | 0.100 |
Why?
|
| Necrosis | 1 | 2012 | 208 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 122 | 0.100 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 99 | 0.090 |
Why?
|
| Reference Values | 2 | 2015 | 710 | 0.090 |
Why?
|
| Laboratories | 1 | 2012 | 82 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2012 | 140 | 0.090 |
Why?
|
| Outpatients | 2 | 2022 | 253 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 116 | 0.090 |
Why?
|
| Syphilis | 1 | 2012 | 96 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2015 | 851 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 170 | 0.090 |
Why?
|
| Heparin Lyase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2010 | 11 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 178 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 129 | 0.090 |
Why?
|
| Coinfection | 1 | 2012 | 169 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 159 | 0.090 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2010 | 98 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 356 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2012 | 682 | 0.090 |
Why?
|
| Incidence | 2 | 2015 | 3138 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 728 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 109 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2022 | 1257 | 0.080 |
Why?
|
| Factor XII | 1 | 2009 | 4 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1585 | 0.080 |
Why?
|
| Hemophilia B | 1 | 2009 | 7 | 0.080 |
Why?
|
| Polycythemia | 1 | 2009 | 43 | 0.080 |
Why?
|
| Middle Aged | 6 | 2024 | 26867 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 192 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 649 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2012 | 366 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2011 | 434 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 729 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 113 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2557 | 0.070 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 634 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2881 | 0.070 |
Why?
|
| Pathology | 1 | 2007 | 39 | 0.070 |
Why?
|
| Risk Factors | 5 | 2019 | 10281 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 377 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2012 | 658 | 0.060 |
Why?
|
| Sepsis | 1 | 2010 | 478 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 436 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 21 | 0.060 |
Why?
|
| Erythrocyte Indices | 1 | 2005 | 15 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 18 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 30 | 0.060 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 13 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 51 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2009 | 940 | 0.060 |
Why?
|
| Transfusion Reaction | 1 | 2025 | 42 | 0.060 |
Why?
|
| Rodenticides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2014 | 4805 | 0.060 |
Why?
|
| Hematuria | 1 | 2004 | 55 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 76 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 183 | 0.060 |
Why?
|
| Factor VIIa | 1 | 2023 | 24 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2019 | 542 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 57 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2006 | 206 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2024 | 209 | 0.050 |
Why?
|
| Animals | 4 | 2018 | 34046 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 770 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 225 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 408 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2013 | 120 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 4631 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 759 | 0.040 |
Why?
|
| Body Weight | 2 | 2017 | 991 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 1889 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 41 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2237 | 0.040 |
Why?
|
| Fibrin | 1 | 2020 | 64 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1397 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 157 | 0.040 |
Why?
|
| Inpatients | 1 | 2003 | 496 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 55 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2019 | 65 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3287 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 235 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2018 | 71 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2902 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 596 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2051 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 24 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 134 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 35 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 221 | 0.030 |
Why?
|
| Body Composition | 1 | 2019 | 522 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 646 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 443 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 556 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1624 | 0.030 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2018 | 679 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 2015 | 8 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 345 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1165 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 590 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 90 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 374 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 174 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 390 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 35 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 968 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 250 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 662 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 324 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 111 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 136 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1160 | 0.030 |
Why?
|
| Software | 1 | 2017 | 683 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 317 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 103 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 570 | 0.020 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 9 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2011 | 19 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 541 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2011 | 73 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1108 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 192 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3586 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2012 | 195 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2011 | 172 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 490 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1780 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5163 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 3 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1311 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2011 | 236 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 290 | 0.020 |
Why?
|
| Factor XI | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5845 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 13 | 0.020 |
Why?
|
| Quality Control | 1 | 2007 | 119 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 332 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19825 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 118 | 0.020 |
Why?
|
| Graft vs Host Reaction | 1 | 2005 | 9 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 1562 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2009 | 681 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 241 | 0.010 |
Why?
|
| United States | 2 | 2011 | 10906 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 177 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3448 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 494 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2448 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2096 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4375 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 17573 | 0.010 |
Why?
|